ArticleScientific reports2020
Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Predictive value of radiomics-based machine learning for the disease-free survival in breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy.Annals of surgical oncology · 2023Trial
- Associations of breast DNA methylation-based measures of biological ageing with obesity-related breast cancer risk markers.Epigenetics · 2026Article
- Highly CD81-expressing stromal cells characterize a tumor-suppressive immune microenvironment in invasive breast cancer.Breast cancer research : BCR · 2026Article
- Noninvasive prediction of Ki67 proliferation index in breast cancer based on integrated photoacoustic imaging.BMC medical imaging · 2026Article
- Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.BMC cancer · 2026Article
- Assessment of Early Breast Cancer Response to Chemotherapy with Ultrasound Radiomics.Diagnostics (Basel, Switzerland) · 2026Article
- Correlates of Ki-67 proliferation index in a cohort of women with suspected breast cancer in Lusaka, Zambia.PLOS global public health · 2026Article
- The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Comparison of Abbreviated MRI and Full Diagnostic Protocol MRI for Surgical Planning in Patients with Newly Diagnosed Breast Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Correlation of Peripheral Neutrophil-to-Lymphocyte Ratio (NLR) with Ki-67 and Other Clinicopathological Parameters of Breast Carcinoma.Indian journal of surgical oncology · 2025Article
- Tumour microbiota activities associated with local recurrence in ER + PR + breast cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Association between Ki-67 and clinical outcomes in 324 Chinese patients with resectable acral melanoma.Scientific reports · 2025Article
- Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients.Discover oncology · 2025Review
- Quantitative proteomics analysis of triple-negative breast cancers.NPJ precision oncology · 2025Article
- Expression of Ki-67 in Invasive Breast Carcinoma and Its Correlation With Different Clinicopathological Features.Cureus · 2024Article
- Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy.Scientific reports · 2024Article
- Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.Breast cancer (Dove Medical Press) · 2024Article
- Preoperative Prediction of Breast Cancer Histological Grade Using Intratumoral and Peritumoral Radiomics Features from T2WI and DWI MR Sequences.Breast cancer (Dove Medical Press) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective analysis evaluated the interaction between Ki-67 and histological grade and their prognostic role in different breast cancer subtypes. In total, 2,573 breast cancer patients underwent surgery, and their histological grade and Ki-67 values were evaluated by breast pathologists. The median Ki-67 index was 15%, which was used as the cut-off for low/high Ki-67 expression. Recurrence-free survival (RFS) was calculated and compared, and the results indicated that Ki-67 expression was significantly associated with histological grade in all breast cancer patients (p < 0.001) and in each immunohistochemical (IHC)-based subtype (p < 0.001). Both high Ki-67 expression and grade 3 tumours were independent predictors of inferior RFS in all patients, especially in those with luminal-like tumours (p < 0.05). Ki-67 was an independent prognostic factor for RFS in grade 1, 2 patients with luminal-like tumours (adjusted hazard ratio [HR] = 1.92, 95% confidence interval [CI]: 1.22-3.03, p = 0.005), but not in the other subtypes. Similarly, histological grade predicted shorter RFS in patients with low Ki-67 expression who had luminal-like tumours (adjusted HR = 2.12, 95% CI: 1.13-3.99, p = 0.02) but not in the other subtypes. Conversely, Ki-67 showed no prognostic value for patients with grade 3 tumours and vice versa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.